See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
Standard treatment of myxopapillary ependymoma is aggressive surgery. It can generally can be cured by gross total surgical resection, and there is usually a favorable prognosis. However, surgery is typically less curative in tumors that are large, multifocal or extend outside the thecal sac. Late recurrences may occur, particularly in pediatric individuals. Treatment strategies may also include radiation, but the use of chemotherapy remains more controversial; chemotherapy has been widely used in pediatric individuals due to more aggressive disease in these individuals. The role of adjuvant chemotherapy or radiotherapy is unclear for the subset of individuals with recurrence or in individuals in whom gross total resection cannot be achieved.
Last updated: 6/8/2011
- Valerie N Barton et al. Unique Molecular Characteristics of Pediatric Myxopapillary Ependymoma. Brain Pathology. May 2010; 20(3):560-570. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871180/?tool=pubmed. Accessed 4/7/2011.
- Shonka NA. Targets for therapy in ependymoma. Targeted Oncology. March 29, 2011; Epub:http://www.ncbi.nlm.nih.gov/pubmed/21445635. Accessed 4/7/2011.
- ClinicalTrials.gov lists trials that are studying or have studied Myxopapillary ependymoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.